Board Member
Bristol Myers Squibb Co (BMY)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Christopher Boerner is recorded as CEO, Board Member and COO at Bristol Myers Squibb Co (BMY). Bristol Myers Squibb Co reported in an 8-K filed May 4, 2023 that Christopher Boerner was appointed member of the Board, effective May 2, 2023. Bristol Myers Squibb Co reported in an 8-K filed May 4, 2023 that Christopher Boerner was appointed Chief Executive Officer, effective November 1, 2023. Bristol Myers Squibb Co reported in an 8-K filed May 4, 2023 that Christopher Boerner was appointed Chief Operating Officer, effective April 26, 2023. The proxy statement of Bristol Myers Squibb Co reports total compensation of $21,879,919 for Christopher Boerner in fiscal 2025, including a base salary of $1,586,346. Disclosed compensation is on record for 4 fiscal years. Christopher Boerner has spoken on 6 earnings calls across 1 company, most recently for Bristol Myers Squibb Co on October 30, 2025.
“On May 2, 2023, the Board elected Dr. Boerner, to serve as a member of the Board, effective May 2, 2023, after the Annual Meeting.”
“On April 26, 2023, Bristol Myers Squibb Company (the "Company") announced that the Board of Directors of the Company ("Board") appointed Christopher Boerner, Ph.D., to serve as the Company's Chief Operating Officer, effective April 26, 2023, and as the Chief Executive Officer, effective November 1, 2023.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2023-05-02–present
2023-04-26–present
Start not stated–present
Proxy statement
Start not stated–2023-03-23
Last confirmed by a filing; no departure on record
Recorded roles and call appearances connecting this person to public companies.
CEO, Board Member, COO
2023-04-26–present
Other people whose current roles at this company are on record from its filings.
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Bristol Myers Squibb Co (BMY) | Board Chair and Chief Executive Officer | $1,586,346 | $21,879,919 |
| 2024 | Bristol Myers Squibb Co (BMY) | Board Chair and Chief Executive Officer | $1,536,538 | $18,787,618 |
| 2023 | Bristol Myers Squibb Co (BMY) | Board Chair and Chief Executive Officer | $1,256,921 | $8,461,833 |
| 2022 | Bristol Myers Squibb Co (BMY) | Board Chair and Chief Executive Officer | $1,064,049 | $6,880,220 |
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
